From India to the world - A better way to prevent cervical cancer

New England Journal of Medicine

Volumn 360, Issue 14, 2009, Pages 1453-1455

  Schiffman, Mark ^a   Wacholder, Sholom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CONDYLOMA ACUMINATUM; EDITORIAL; INDIA; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; MASS SCREENING; MORTALITY; NOTE; PAPILLOMA VIRUS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIRUS INFECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 63849142320     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0901167     Document Type: Editorial

References (13)

1. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394
2. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398-406.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
4. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104 (Pubitemid 41653100)
5. Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 2006;24:Suppl 3:S3/114-S3/121.
6. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43:Suppl:S5-S25.
7. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-936
8. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772
9. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-1588
10. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597
11. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079
12. Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
13. Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-517